Drug shortage
Remifentanil Hydrochloride Injection · Mylan Institutional, a Viatris Company
FDA drug shortage · Current · updated Oct 5, 2026
Key facts
| Generic name | Remifentanil Hydrochloride Injection |
|---|---|
| Company | Mylan Institutional, a Viatris Company |
| Presentation | Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01) |
| Dosage form | Injection |
| Status | Current |
| Therapeutic category | Analgesia/Addiction |
| Package NDCs | 72078-034-01 |
| First posted | Jun 28, 2022 |
| Last updated | Oct 5, 2026 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: